Alyeska Investment Group Portfolio holdings
AUM
$28.2B
1-Year Return
38.86%
This Quarter Return
+9.63%
1 Year Return
+38.86%
3 Year Return
+101.95%
5 Year Return
+160.93%
10 Year Return
+424.53%
AUM
$16.1B
AUM Growth
+$1.17B
(+7.9%)
Cap. Flow
-$35.2M
Cap. Flow
% of AUM
-0.22%
Top 10 Holdings %
Top 10 Hldgs %
13.92%
Holding
646
New
153
Increased
115
Reduced
140
Closed
146
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
$269M |
| 2 |
Broadcom
AVGO
|
$192M |
| 3 |
AstraZeneca
AZN
|
$150M |
| 4 |
Intuitive Surgical
ISRG
|
$150M |
| 5 |
TE Connectivity
TEL
|
$146M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$480M |
| 2 |
AerCap
AER
|
$204M |
| 3 |
Western Digital
WDC
|
$184M |
| 4 |
Akamai
AKAM
|
$127M |
| 5 |
Illumina
ILMN
|
$112M |
Sector Composition
| 1 | Technology | 22.16% |
| 2 | Consumer Discretionary | 14.37% |
| 3 | Industrials | 13.47% |
| 4 | Healthcare | 12.99% |
| 5 | Financials | 9.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
TransDigm Group
TDG
$71.6B
| $833K | 0.01% |
+676
| New | +$833K |
|
402
Trane Technologies
TT
$92.1B
| $814K | 0.01% |
+2,710
| New | +$814K |
|
403
Acuity Brands
AYI
$10.4B
| $792K | ﹤0.01% |
+2,946
| New | +$792K |
|
404
Cytek Biosciences
CTKB
$511M
| $671K | ﹤0.01% |
100,000
| – | – |
|
405
Caribou Biosciences
CRBU
$174M
| $643K | ﹤0.01% |
125,000
| – | – |
|
406
Cummins
CMI
$55.1B
| $577K | ﹤0.01% |
+1,957
| New | +$577K |
|
407
Banc of California
BANC
$2.65B
| $562K | ﹤0.01% |
+36,959
| New | +$562K |
|
408
Welltower
WELL
$112B
| $541K | ﹤0.01% |
5,790
-50,415
| -90% | -$4.71M |
|
409
Marvell Technology
MRVL
$54.6B
| $531K | ﹤0.01% |
+7,486
| New | +$531K |
|
410
IN8bio
INAB
$9.85M
| $526K | ﹤0.01% |
14,867
-12,455
| -46% | -$441K |
|
|
OTLY
411
Oatly Group
OTLY
$524M
| $418K | ﹤0.01% |
+18,484
| New | +$418K |
|
412
Applovin
APP
$166B
| $417K | ﹤0.01% |
+6,029
| New | +$417K |
|
|
VBIV
413
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $377K | ﹤0.01% |
626,436
| – | – |
|
414
Hyperfine
HYPR
$91.9M
| $375K | ﹤0.01% |
375,000
| – | – |
|
415
Tonix Pharmaceuticals
TNXP
$233M
| $372K | ﹤0.01% |
625
-220
| -26% | -$131K |
|
416
AN2 Therapeutics
ANTX
$34.4M
| $325K | ﹤0.01% |
100,000
+50,000
| +100% | +$163K |
|
417
Surrozen
SRZN
$105M
| $320K | ﹤0.01% |
20,376
| – | – |
|
418
CalciMedica
CALC
$43M
| $312K | ﹤0.01% |
+75,082
| New | +$312K |
|
419
Owens Corning
OC
$13B
| $282K | ﹤0.01% |
+1,690
| New | +$282K |
|
420
Clene
CLNN
$60.2M
| $202K | ﹤0.01% |
23,707
-60,638
| -72% | -$516K |
|
|
AFMD
421
DELISTED
Affimed
AFMD
| $186K | ﹤0.01% |
35,000
| – | – |
|
422
Alto Neuroscience
ANRO
$99.4M
| $154K | ﹤0.01% |
+10,000
| New | +$154K |
|
|
AXDX
423
DELISTED
Accelerate Diagnostics
AXDX
| $79.7K | ﹤0.01% |
+80,547
| New | +$79.7K |
|
424
Norfolk Southern
NSC
$62.3B
| – | – |
-3,517
| Closed | -$831K |
|
425
Realty Income
O
$54.2B
| – | – |
-464,688
| Closed | -$26.7M |
|